Our results, together with those of our previous study on patients receiving immunotherapy [5], are reassuring with regards to the medical treatment of melanoma patients carrying germline CDKN2A PV, and we believe this is a valuable and novel addition to the genetic counseling of these patients. The gene discussed is CDKN2A; the disease is melanoma.